Rethinking Treatment Goals in Psoriasis: Leveraging IL-17 Inhibitors to Move Beyond Skin Clearance Toward PsA Prevention - Episode 8
Bimekizumab in Psoriasis: EADV 2025 Insights and Approaches to Patient Monitoring
The panelists review EADV 2025 data evaluating whether bimekizumab may help prevent PsA development in patients with psoriasis only. The study followed psoriasis patients prospectively and stratified risk using clinical factors and a patient questionnaire (PASE), treating scores <47 as low risk and ≥47 as high risk. Among patients with >1 risk factor treated with bimekizumab, over 96% maintained PASE scores <47 on longitudinal follow-up—used here as a patient-reported surrogate for not developing PsA symptoms (noting the limitation of no comparator arm). These findings align with real-world practice that prioritizes identifying high-risk patients and monitoring symptom trajectories over time. Overall, the experts interpret the stratified results as supportive—though preliminary—evidence that sustained IL-17A/F blockade may reduce transition to PsA in higher-risk psoriasis populations, while emphasizing the need for prospective, comparative data.
The panelists review EADV 2025 data evaluating whether bimekizumab may help prevent PsA development in patients with psoriasis only. The study followed psoriasis patients prospectively and stratified risk using clinical factors and a patient questionnaire (PASE), treating scores <47 as low risk and ≥47 as high risk. Among patients with >1 risk factor treated with bimekizumab, over 96% maintained PASE scores <47 on longitudinal follow-up—used here as a patient-reported surrogate for not developing PsA symptoms (noting the limitation of no comparator arm). These findings align with real-world practice that prioritizes identifying high-risk patients and monitoring symptom trajectories over time. Overall, the experts interpret the stratified results as supportive—though preliminary—evidence that sustained IL-17A/F blockade may reduce transition to PsA in higher-risk psoriasis populations, while emphasizing the need for prospective, comparative data.
